EHS & Quality Software for Pharma & Biotech

Pharma and biotech are the sector where EHS and quality stop being separate functions and become one quality system, because the regulator reads them together. The manufacturing floor operates under cGMP — FDA 21 CFR Parts 210 and 211 for finished drugs, 21 CFR Part 11 for the electronic records and signatures that make the batch record trustworthy, and EU GMP Annex 1 for sterile manufacturing, revised in 2022 to put the contaminated-environment risk at the centre of the sterile programme. The API manufacturer runs ICH Q7, and the quality system across the sector runs on ICH Q9 for risk and ICH Q10 for the pharmaceutical quality system, with the deviation-CAPA-change control loop as the operational engine that keeps the licence.

The deviation is where the EHS and the GMP quality meet. A deviation from a procedure is a GMP event; a deviation that released a solvent vapour or a containment breach is an EHS event, and on a potent-compound or a biologic the same event is both. The OSHA side runs 29 CFR 1910.1200 HazCom for the API and intermediates, 29 CFR 1910.1030 bloodborne pathogens for the biologic and cell-culture side, and the EPA side runs RCRA for the pharma waste stream and the P-listed and U-listed acute hazardous waste. The supplier qualification runs the same deviation-CAPA loop outward — the supplier deviation is your deviation under the GMP quality agreement.

The validation burden is what makes pharma a software problem. The CSV — computer system validation under GAMP 5 — means the EHS and quality system itself has to be specified, tested, and documented to a rigour the platform vendor carries, and the audit trail and the electronic signature under 21 CFR Part 11 are not features but the licence to use the system in a GxP process. A QEHS platform for pharma holds the deviation against the CAPA against the change control against the supplier, with the audit trail and the e-signature that let the system live inside the validated state, not alongside it.